首页> 美国卫生研究院文献>ACS AuthorChoice >CB2-Selective CannabinoidReceptor Ligands: SynthesisPharmacological Evaluation and Molecular Modeling Investigation of18-Naphthyridin-2(1H)-one-3-carboxamides
【2h】

CB2-Selective CannabinoidReceptor Ligands: SynthesisPharmacological Evaluation and Molecular Modeling Investigation of18-Naphthyridin-2(1H)-one-3-carboxamides

机译:CB2选择性大麻素受体配体:合成药理学评价和分子模型研究18-萘啶-2(1H)-一-3-羧酰胺

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have recently identified 1,8-naphthyridin-2(1H)-one-3-carboxamide as a new scaffold very suitable for the development of new CB2 receptor potent and selective ligands. In this paper we describe a number of additional derivatives in which the same central scaffold has been variously functionalized in position 1 or 6. All new compounds showed high selectivity and affinity in the nanomolar range for the CB2 receptor. Furthermore, we found that their functional activity is controlled by the presence of the substituents at position C-6 of the naphthyridine scaffold. In fact, the introduction of substituents in this position determined a functionality switch from agonist to antagonists/inverse agonists. Finally, docking studies showed that the difference between the pharmacology of these ligands may be in the ability/inability to block the Toggle Switch W6.48(258) (χ1 g+ → trans) transition.
机译:我们最近确定了1,8-萘啶-2(1H)-一-3-羧酰胺是一种非常适合开发新型CB2受体有效和选择性配体的新型支架。在本文中,我们描述了许多其他衍生物,其中相同的中央支架在1或6位具有各种功能。所有新化合物在纳摩尔范围内对CB2受体均显示出高选择性和亲和力。此外,我们发现它们的功能活性受萘啶支架C-6位上取代基的存在控制。实际上,在该位置引入取代基决定了功能从激动剂转变为拮抗剂/反向激动剂。最后,对接研究表明,这些配体的药理学差异可能在于阻止/不能阻断拨动开关W6.48(258)(χ1g +→反式)过渡的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号